Pemetrexed

Generic Name
Pemetrexed
Brand Names
Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
Drug Type
Small Molecule
Chemical Formula
C20H21N5O6
CAS Number
137281-23-3
Unique Ingredient Identifier
04Q9AIZ7NO
Background

Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...

Indication

Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions
Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
Associated Therapies
Monotherapy
Clinical Trials
Related News

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

First Posted Date
2023-02-10
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
377
Registration Number
NCT05722015
Locations
🇭🇺

Törökbálinti Tüdőgyógyintézet ( Site 2105), Törökbálint, Pest, Hungary

🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 4207), Kaohsiung, Taiwan

🇺🇸

St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023), Phoenix, Arizona, United States

and more 107 locations

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

First Posted Date
2023-02-06
Last Posted Date
2024-01-16
Lead Sponsor
Hackensack Meridian Health
Target Recruit Count
108
Registration Number
NCT05715229
Locations
🇺🇸

John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, United States

🇺🇸

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States

🇺🇸

Jersey Shore University Medical Center, Neptune, New Jersey, United States

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

First Posted Date
2023-01-19
Last Posted Date
2024-10-26
Lead Sponsor
Nikolaj Frost MD
Target Recruit Count
136
Registration Number
NCT05689671
Locations
🇩🇪

LungenClinic Großhansdorf GmbH, Großhansdorf, Germany

🇩🇪

Universitätsmedizin Göttingen, Göttingen, Germany

🇩🇪

Asklepios Klinkum Hamburg, Hamburg, Germany

and more 28 locations

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

First Posted Date
2023-01-18
Last Posted Date
2024-12-02
Lead Sponsor
AstraZeneca
Target Recruit Count
1350
Registration Number
NCT05687266
Locations
🇻🇳

Research Site, Ho Chi Minh, Vietnam

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

First Posted Date
2023-01-12
Last Posted Date
2024-05-06
Lead Sponsor
Baptist Health South Florida
Target Recruit Count
15
Registration Number
NCT05681195
Locations
🇺🇸

Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

First Posted Date
2022-12-27
Last Posted Date
2023-02-24
Lead Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Target Recruit Count
240
Registration Number
NCT05664971
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Phase 1
Recruiting
Conditions
NSCLC
Interventions
Drug: AK119
Drug: AK112
Drug: Pemetrexed
Drug: Carboplatin
First Posted Date
2022-12-05
Last Posted Date
2023-03-09
Lead Sponsor
Akeso
Target Recruit Count
114
Registration Number
NCT05636267
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, China

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

First Posted Date
2022-12-02
Last Posted Date
2024-10-23
Lead Sponsor
BeiGene
Target Recruit Count
400
Registration Number
NCT05635708
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇦🇺

Chris Obrien Lifehouse, Camperdown, New South Wales, Australia

🇰🇷

Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do, Korea, Republic of

and more 61 locations

Study of Novel Treatment Combinations in Patients With Lung Cancer

First Posted Date
2022-12-01
Last Posted Date
2024-11-14
Lead Sponsor
Gilead Sciences
Target Recruit Count
593
Registration Number
NCT05633667
Locations
🇧🇷

Hospital Mae de Deus, Porto Alegre, Brazil

🇧🇷

Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03, Porto Alegre, Brazil

🇬🇧

Birmingham Heartlands Hospital,Substudy-03, Birmingham, United Kingdom

and more 80 locations

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

First Posted Date
2022-11-22
Last Posted Date
2024-11-28
Lead Sponsor
NRG Oncology
Target Recruit Count
474
Registration Number
NCT05624996
Locations
🇺🇸

UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States

🇺🇸

Ascension Borgess Hospital, Kalamazoo, Michigan, United States

🇺🇸

Benefis Sletten Cancer Institute, Great Falls, Montana, United States

and more 335 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy